A REVIEW ON NANOPARTICLE TECHNOLOGY FOR DERMAL DRUG DELIVERY

Mohit[1*], Jaya Martolia[2], Neha P Singh[3]

ArticleHistory: Received: 03.05.2023 **Revised:**16.06.2023 **Accepted:** 10.07.2023

Abstract

Nanoparticle technology has emerged as a promising approach for dermal drug delivery due to its ability to improve drug penetration into the skin, enhance drug stability, and minimize side effects. Various types of nanoparticles, including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and inorganic nanoparticles, have been explored for dermal drug delivery. The characteristics of nanoparticles, such as size, surface charge, and surface modification, can significantly affect their dermal penetration and drug release. Formulation factors, including surfactants and stabilizers, can also impact nanoparticle performance. In vitro and in vivo models are commonly used to evaluate the efficacy and safety of nanoparticle-based dermal drug delivery. Despite the potential benefits, there are also safety concerns associated with nanoparticle use, which require further investigation. Regulatory considerations must also be taken into account when developing nanoparticle-based dermal drug delivery systems. Future research should focus on addressing the challenges associated with nanoparticle-based dermal drug delivery, such as safety and regulatory issues, and exploring the potential applications of nanoparticle technology for combination therapy and transdermal delivery of larger molecules. Overall, nanoparticle-based dermal drug delivery holds great promise for improving the treatment of various dermatological conditions.

Keywords - Nanoparticles, Dermal Drug Delivery,Transdermal Delivery.

[1]Research Scholar, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, India
[2]Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, India
[3]Assistant Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, India

Email: [1]Mohitantil3836@gmail.com

DOI: 10.31838/ecb/2023.12.s3.643

1. Introduction

Dermal drug delivery refers to the delivery of drugs through the skin for local or systemic effects. It is an important route of drug administration as it offers several advantages over other routes, such as oral or intravenous delivery.[1]

One of the main advantages of dermal drug delivery is the avoidance of the first-pass metabolism that occurs when drugs are administered orally. This can result in a more targeted and efficient delivery of drugs to the desired site of action. Dermal drug delivery also provides a non-invasive and painless mode of drug delivery, which is particularly useful for patients who cannot tolerate injections or have difficulty swallowing pills.[2]

Moreover, dermal drug delivery can be used for both local and systemic treatment of various conditions, including skin diseases, infections, pain, and inflammation. The skin also provides a barrier function, which can be exploited to control drug release and enhance drug permeation across the skin. Therefore, dermal drug delivery has a wide range of applications and is an important area of research for the development of new drug delivery systems.[3,4]

Limitations of conventional dermal drug delivery methods

Conventional dermal drug delivery methods, such as topical creams, ointments, and gels, have several limitations that can impact their effectiveness. Some of these limitations include:

1. Poor drug penetration: The outermost layer of the skin, the stratum corneum, acts as a barrier that limits drug penetration into deeper skin layers. This can result in poor drug efficacy, particularly for drugs with poor skin permeation properties.[5]
2. Inconsistent drug absorption: Dermal drug absorption can be affected by various factors, such as skin hydration, skin thickness, and the presence of skin diseases or conditions. This can result in inconsistent drug absorption and variability in drug efficacy.[6]
3. Local side effects: Topical drug delivery can cause local side effects, such as skin irritation, redness, and burning sensation. These side effects can limit patient compliance and reduce the effectiveness of the drug.[7]
4. Limited drug stability: Some drugs may be susceptible to degradation or inactivation when exposed to the skin's environment, such as heat, light, and moisture. This can limit the shelf-life and effectiveness of the drug.[8]
5. Difficulty in delivering large molecules: Conventional dermal drug delivery methods have limited ability to deliver large molecules, such as proteins and peptides, due to their large molecular size and poor skin penetration properties.[9]

Role of nanoparticle technology in dermal drug delivery

Nanoparticle technology has emerged as a promising approach for dermal drug delivery due to its ability to overcome the limitations of conventional drug delivery methods. Nanoparticles are submicron-sized particles (typically less than 1000 nm in diameter) that can be loaded with drugs and designed to target specific skin layers or cells.[10]

Nanoparticles have several advantages over conventional drug delivery methods for dermal drug delivery:

1. Improved drug penetration: Nanoparticles can penetrate the skin's barrier and deliver drugs to deeper skin layers, resulting in improved drug efficacy.[11]
2. Controlled drug release: Nanoparticles can be designed to release drugs in a controlled

manner, which can improve drug absorption and reduce local side effects.[12]

3. Enhanced drug stability: Nanoparticles can protect drugs from degradation or inactivation, improving their shelf-life and effectiveness.[13]
4. Increased drug solubility: Nanoparticles can improve drug solubility and bioavailability, resulting in improved drug efficacy.[14]
5. Targeted drug delivery: Nanoparticles can be designed to target specific skin layers or cells, resulting in improved drug efficacy and reduced side effects.[15]

Several types of nanoparticles, such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles, have been studied for dermal drug delivery. These nanoparticles can be loaded with a variety of drugs, including small molecules, proteins, and peptides.[16]

Nanoparticles for dermal drug delivery

Nanoparticles are being extensively used in dermal drug delivery as they offer several advantages over conventional drug delivery methods. Here are some of the commonly used types of nanoparticles for dermal drug delivery:

Liposomes

Liposomes are lipid-based nanoparticles that are composed of a phospholipid bilayer and an aqueous core. They have been extensively studied for dermal drug delivery because of their ability to encapsulate both hydrophilic and lipophilic drugs. The lipid bilayer structure of liposomes is similar to the cell membrane, making them biocompatible and biodegradable.[17]

One of the advantages of using liposomes for dermal drug delivery is their ability to improve drug solubility, stability, and bioavailability. Liposomes can encapsulate hydrophilic drugs in the aqueous core, while lipophilic drugs can be incorporated into the lipid bilayer. This allows liposomes to deliver drugs that are poorly soluble in water or have low bioavailability.[18]

Liposomes can also enhance the skin penetration of drugs by altering the lipid composition of the stratum corneum, which is the outermost layer of the skin. The lipid bilayer of the liposome can interact with the lipid bilayer of the stratum corneum, disrupting its barrier function and increasing the thermodynamic activity of the drug. This results in improved drug penetration and efficacy.[19]

Another advantage of using liposomes for dermal drug delivery is their ability to provide a controlled release mechanism. Liposomes can be designed to release drugs in a sustained and controlled manner, which can reduce the frequency of drug administration and improve patient compliance. Liposomes can also reduce the toxicity of some drugs by providing a protective barrier between the drug and the skin, thereby minimizing the risk of local and systemic toxicity.[20]

However, liposomes also have some limitations that need to be addressed. One of the limitations is their poor stability, especially in the presence of serum or other biological fluids. The lipid bilayer of the liposome can be easily destabilized by changes in temperature, pH, and osmotic pressure, leading to drug leakage and reduced efficacy. Another limitation is the low drug loading capacity of liposomes, which can limit the amount of drug that can be delivered.[21]

Polymeric nanoparticles

Polymeric nanoparticles are another type of nanoparticle that has been extensively studied for dermal drug delivery. These nanoparticles are composed of biodegradable and biocompatible polymers, such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), chitosan, and polycaprolactone (PCL).

Polymeric nanoparticles have several advantages for dermal drug delivery, including improved drug solubility, stability, and bioavailability.[22]

One of the advantages of polymeric nanoparticles is their ability to control drug release. The release rate of drugs from polymeric nanoparticles can be controlled by modifying the polymer composition, particle size, and surface charge. This allows for a sustained release of drugs over an extended period of time, which can improve drug efficacy and patient compliance.[23]

Polymeric nanoparticles can also improve drug penetration through the skin. These nanoparticles can be designed to target specific skin layers, such as the epidermis, dermis, or hair follicles, by modifying their size, shape, and surface chemistry. This targeted delivery can improve drug efficacy and minimize local and systemic toxicity.[24]

Another advantage of polymeric nanoparticles is their ability to protect drugs from degradation and enhance their stability. Polymeric nanoparticles can encapsulate drugs, protecting them from exposure to light, oxygen, and other environmental factors that can degrade their efficacy. Polymeric nanoparticles can also protect drugs from enzymatic degradation, which can improve their bioavailability.[25]

However, polymeric nanoparticles also have some limitations that need to be addressed. One of the limitations is their potential toxicity, which can be caused by the release of toxic degradation products from the polymers used to make the nanoparticles. This can lead to local and systemic toxicity, which can limit their use in clinical settings. Another limitation is their poor stability, especially in the presence of biological fluids, which can lead to drug leakage and reduced efficacy.[26]

Dendrimers

Dendrimers are a type of branched, nanoscale polymer that has been investigated for use in dermal drug delivery. They consist of a central core molecule with multiple branches or dendrons that radiate outwards, creating a highly branched, spherical structure. The branches of dendrimers can be functionalized with various chemical groups, allowing for precise control over their properties and interactions with biological systems.[27]

One of the advantages of dendrimers is their ability to encapsulate drugs within their interior or attach drugs to their surface. The size and shape of dendrimers can be controlled with high precision, allowing for the design of nanoparticles with specific drug loading and release properties. This can enable the sustained release of drugs over an extended period of time, which can improve drug efficacy and reduce the frequency of dosing.[28]

Dendrimers can also improve drug penetration through the skin. The small size of dendrimers allows them to penetrate deeply into the skin layers, including the stratum corneum, the outermost layer of the skin. This can enhance the delivery of drugs to target tissues and improve their efficacy. Dendrimers can also be designed to target specific skin layers or cell types, such as hair follicles or immune cells, which can enhance drug uptake and reduce systemic toxicity.[29]

In addition, dendrimers have a low toxicity profile compared to other nanoparticle types. Their branched, spherical structure allows for efficient clearance from the body, reducing the risk of long-term accumulation and toxicity. Dendrimers can also be functionalized with biocompatible and biodegradable materials, further enhancing their biocompatibility.However, there are also some limitations of dendrimers for dermal drug delivery. One of the main limitations is the difficulty in producing dendrimers at large scales and

high purities, which can limit their clinical translation. The high cost of producing dendrimers also presents a challenge for their widespread use in dermal drug delivery.[30]

Solid lipid nanoparticles (SLNs):

Solid lipid nanoparticles (SLNs) are another type of nanoparticle that have been investigated for dermal drug delivery. They are composed of a solid lipid matrix, typically made of biocompatible and biodegradable lipids such as triglycerides, fatty acids, and waxes. The lipid matrix can encapsulate drugs or other active agents, which can be released over time upon contact with the skin.[31]

One of the advantages of SLNs is their ability to improve drug solubility and stability, particularly for poorly soluble drugs. The lipid matrix can increase the solubility of hydrophobic drugs and protect them from degradation or oxidation, which can improve their bioavailability and efficacy.[32]

SLNs can also enhance drug penetration through the skin. The small size of SLNs allows them to penetrate deeply into the skin layers, including the stratum corneum, where they can release drugs and enhance drug uptake. The lipid matrix of SLNs can also interact with the lipid-rich stratum corneum, increasing the permeability of the skin barrier and facilitating drug penetration.[33]

In addition, SLNs have a low toxicity profile and can be easily prepared using simple, scalable techniques. The use of biocompatible and biodegradable lipids in SLNs further enhances their safety profile and reduces the risk of toxicity or allergic reactions.However, there are also some limitations of SLNs for dermal drug delivery. One of the main limitations is their potential for drug leakage and instability upon storage or exposure to environmental factors such as temperature or pH. The lipid matrix of SLNs can also limit the drug loading capacity and release rate of the nanoparticles, which can affect their efficacy.[34]

Nanostructured lipid carriers (NLCs)

Nanostructured lipid carriers (NLCs) are a type of nanoparticle that are composed of a mixture of solid and liquid lipids. The solid lipid serves as a matrix, while the liquid lipid helps to prevent crystallization and improve the drug loading capacity of the particle. NLCs are typically prepared using high-pressure homogenization, hot homogenization, or solvent emulsification methods.[35]

NLCs have several advantages for dermal drug delivery. First, their small size allows for efficient penetration into the skin, which can improve drug bioavailability. Additionally, the solid lipid matrix can help to protect the drug from degradation and provide sustained release over time. Finally, the use of NLCs can reduce the irritation and sensitization associated with some conventional topical drug formulations.[36]

NLCs have been studied for the delivery of a variety of drugs, including antifungal agents, anti-inflammatory drugs, and cosmetic actives. They have been shown to improve the efficacy of these drugs compared to conventional formulations, as well as reduce their side effects.Overall, NLCs are a promising platform for dermal drug delivery, but further research is needed to optimize their formulation and performance for specific applications.[37,38]

Inorganic nanoparticles

Inorganic nanoparticles are small particles made from metals or metal oxides, such as gold, silver, titanium dioxide, or zinc oxide. Due to their small size and large surface area, they have unique physical and chemical properties that make them attractive for dermal drug delivery.[39]

Gold nanoparticles, for example, have been used to deliver anticancer drugs to skin cancer cells. The gold nanoparticles can be functionalized with targeting

ligands that recognize specific molecules on cancer cells, enabling selective drug delivery. Additionally, gold nanoparticles can enhance the penetration of drugs through the skin by creating temporary pores in the skin barrier, allowing the drug to pass through more easily.[40]

Silver nanoparticles have shown promise as antibacterial agents in topical formulations. They can disrupt the cell membrane of bacteria, leading to their death. Silver nanoparticles have been used to develop dressings for the treatment of infected wounds, as well as topical formulations for the treatment of acne and other skin infections.[41]

Titanium dioxide nanoparticles have been used in sunscreen formulations to provide protection from UV radiation. These nanoparticles absorb UV radiation, preventing it from penetrating the skin and causing damage. Zinc oxide nanoparticles also have similar properties and have been used in sunscreens and other cosmetic products.[42]

Despite their potential advantages, inorganic nanoparticles also have some potential drawbacks. They may be more likely to cause skin irritation or toxicity compared to other nanoparticle types. Additionally, there are concerns about the environmental impact of nanoparticles, particularly if they are not disposed of properly.[43]

Characteristics of nanoparticles affecting their dermal penetration and drug release

The characteristics of nanoparticles can significantly affect their ability to penetrate the skin and release drugs. Some of the key characteristics include:

1. Size: Nanoparticles with smaller sizes generally exhibit greater skin penetration due to their ability to pass through the stratum corneum. However, excessively small particles may be susceptible to aggregation and have a shorter circulation time.[44]
2. Surface charge: Nanoparticles with a positive surface charge may interact more favorably with negatively charged skin surfaces, leading to enhanced skin penetration. However, overly positive particles may interact with other positively charged molecules in the skin, leading to aggregation and hindered penetration.[45]
3. Shape: Nanoparticles with elongated or rod-like shapes have been shown to penetrate skin more efficiently than spherical particles.[46]
4. Surface coating: The surface coating of nanoparticles can significantly affect their skin penetration and drug release properties. For example, hydrophobic coatings can enhance drug loading, while hydrophilic coatings can promote better dispersion in water-based formulations.[47]
5. Drug properties: The properties of the drug being delivered can also impact nanoparticle penetration and release. Highly lipophilic drugs may require nanoparticles with hydrophobic surfaces to achieve efficient delivery, while hydrophilic drugs may require nanoparticles with hydrophilic coatings.[48]
6. Composition: The composition of nanoparticles can affect their ability to penetrate the skin and release drugs. For example, nanoparticles made from biocompatible and biodegradable materials may be less likely to cause skin irritation and inflammation.[49]
7. Solubility: The solubility of nanoparticles in different media (e.g., water, oil, lipids) can affect their stability, drug loading capacity, and skin penetration. For example, nanoparticles that are

insoluble in water may require a surfactant to stabilize them in an aqueous environment.[50]

8. Aggregation: Nanoparticles that aggregate can be too large to penetrate the skin or may cause skin irritation. Therefore, preventing nanoparticle aggregation is an important consideration in dermal drug delivery.[51]
9. Zeta potential: The zeta potential of nanoparticles can indicate their stability and potential for aggregation. Nanoparticles with a high zeta potential may be more stable and less likely to aggregate, while those with a low zeta potential may be more prone to aggregation.[52]
10. Surface energy: The surface energy of nanoparticles can affect their interaction with the skin and drug release. For example, nanoparticles with a high surface energy may be more likely to adhere to the skin and have slower drug release kinetics.[53]

Advantages of nanoparticle-based dermal drug delivery

Nanoparticle-based dermal drug delivery has several advantages over conventional drug delivery methods. Some of these advantages are:

1. Enhanced drug efficacy: Nanoparticle-based drug delivery can improve the efficacy of drugs by enhancing their solubility, stability, and bioavailability. This can lead to better therapeutic outcomes for patients.[54]
2. Targeted drug delivery: Nanoparticles can be designed to target specific cells or tissues in the skin, which can improve drug delivery to the desired site and reduce systemic side effects.[55]
3. Controlled drug release: Nanoparticles can be engineered to release drugs at a controlled rate, which can prolong the drug's therapeutic effect and reduce the need for frequent dosing.[56]
4. Improved skin penetration: Nanoparticles can improve the penetration of drugs through the skin by overcoming the skin's natural barrier function.[57]
5. Reduced toxicity: By reducing the dose required for therapeutic effect, nanoparticle-based drug delivery can reduce the toxicity associated with certain drugs.[58]
6. Easy to formulate: Nanoparticle-based drug delivery systems are relatively easy to formulate and can be produced using a variety of techniques, including emulsification, solvent evaporation, and supercritical fluid technology.[59]

Factors affecting nanoparticle dermal delivery

Skin anatomy and barrier function

Skin anatomy and barrier function play a crucial role in nanoparticle dermal delivery. The skin is composed of three main layers: the epidermis, dermis, and subcutaneous layer. The stratum corneum, the outermost layer of the epidermis, is the primary barrier for the penetration of nanoparticles into the skin. The stratum corneum is composed of dead keratinocytes, lipids, and natural moisturizing factors, which provide the skin's barrier properties.[60]

The size, shape, and surface charge of nanoparticles can affect their penetration through the stratum corneum. Nanoparticles with smaller sizes can penetrate the skin more efficiently than larger nanoparticles due to their increased surface area and reduced diffusion distance. Additionally, nanoparticles with a positive surface charge can enhance skin penetration through electrostatic interactions with the negatively charged stratum corneum.[61]

Moreover, the surface coating of nanoparticles can also influence skin penetration. Surface coatings, such as surfactants or polymers, can modify the surface charge and hydrophilicity of nanoparticles, altering their interactions with the stratum corneum and improving their penetration.[62,63]

Finally, skin hydration also plays a crucial role in the penetration of nanoparticles. Hydration of the stratum corneum increases its permeability, allowing for more efficient penetration of nanoparticles. However, excessively hydrated skin can reduce nanoparticle penetration due to the formation of a water barrier on the skin surface.[64]

Physicochemical properties of nanoparticles

Physicochemical properties of nanoparticles are important factors affecting their dermal delivery. Some of these properties are:

1. Size: Nanoparticles with smaller size have higher penetration and permeation ability through the skin.[65]
2. Surface charge: The surface charge of nanoparticles affects their interaction with the skin. Positively charged nanoparticles have higher penetration ability than negatively charged or neutral nanoparticles.[66]
3. Hydrophilicity/hydrophobicity: Hydrophilic nanoparticles have a higher tendency to remain in the superficial layers of the skin, whereas hydrophobic nanoparticles have higher penetration ability.[67]
4. Surface functionalization: Surface functionalization of nanoparticles can improve their stability, biocompatibility, and interaction with skin cells.[68]
5. Crystallinity: The crystallinity of nanoparticles affects their solubility, degradation, and drug release.[69]

Formulation factors (e.g., surfactants, stabilizers)

Formulation factors such as surfactants and stabilizers play an important role in the development of nanoparticle-based dermal drug delivery systems. These factors are critical in achieving stable, well-dispersed nanoparticles with optimal physicochemical properties for effective dermal delivery.[70]

Surfactants are commonly used in nanoparticle formulations to improve their solubility and stability. These molecules contain both hydrophobic and hydrophilic regions, allowing them to form micelles around hydrophobic nanoparticles and disperse them in aqueous solutions. In addition to improving solubility and stability, surfactants can also influence the size and surface charge of nanoparticles, which can impact their skin penetration and cellular uptake. However, high concentrations of surfactants can be cytotoxic and may cause skin irritation or other adverse effects.[71]

Stabilizers are another important formulation factor in nanoparticle-based dermal drug delivery. Stabilizers help to prevent aggregation and maintain the stability of nanoparticles in solution. Common stabilizers include polymers, such as polyvinyl alcohol (PVA), polyethylene glycol (PEG), and polyvinylpyrrolidone (PVP). These polymers can adsorb onto the surface of nanoparticles, providing steric stabilization and preventing aggregation. The choice of stabilizer can also influence the size and surface charge of nanoparticles, which can affect their skin penetration and cellular uptake.[72,73]

Other formulation factors, such as pH, temperature, and ionic strength, can also affect the stability and

physicochemical properties of nanoparticles. For example, changes in pH can cause protonation or deprotonation of surface functional groups on nanoparticles, which can alter their surface charge and influence their skin penetration. Similarly, changes in temperature or ionic strength can cause nanoparticles to aggregate or destabilize.[74]

In vitro and in vivo models for evaluating dermal drug delivery

In vitro and in vivo models are commonly used to evaluate the efficacy of dermal drug delivery systems. In vitro models are used to assess the drug release and penetration of nanoparticles into the skin, whereas in vivo models are used to evaluate the pharmacokinetics, pharmacodynamics, and toxicity of the drug in the skin and the systemic circulation.[75]

In vitro models:

1. Franz diffusion cell: It is the most widely used in vitro model for evaluating dermal drug delivery. The cell consists of a donor compartment, receptor compartment, and a skin membrane mounted between them. The nanoparticles are applied to the donor compartment, and the amount of drug released and penetrated through the skin membrane is measured.[76,77]
2. Tape stripping: It is a non-invasive method used to sample the skin layers. The skin is first treated with the nanoparticles, and then the surface is stripped with adhesive tape to remove the layers of skin. The amount of drug that is retained in each layer is then analyzed.[76,77]
3. Skin explants: This involves excising skin from the animal or human and then using it for in vitro studies. The nanoparticles are applied to the skin explants, and the penetration of the drug is analyzed by histology or microscopy.[76,77]

In vivo models:

1. Animal models: The nanoparticles are applied to the skin of animals such as mice, rats, rabbits, or pigs, and the amount of drug in the skin and the systemic circulation is measured over time.[78,79]
2. Human studies: Human studies involve the application of nanoparticles to the skin of volunteers, and the pharmacokinetics, pharmacodynamics, and toxicity of the drug are assessed.[78,79]

The choice of model depends on the purpose of the study, the nature of the drug and nanoparticles, and ethical considerations. In vitro models provide a cost-effective and fast screening tool, whereas in vivo models are more complex and time-consuming but provide a more realistic representation of human skin.

Applications of nanoparticle-based dermal drug delivery

Nanoparticle-based dermal drug delivery has various applications in the pharmaceutical industry, including:

1. Topical delivery of small molecules: Nanoparticles can be used to deliver small molecule drugs, such as anti-inflammatory drugs, antibiotics, and antifungal agents, to treat various dermatological disorders. For instance, nanoemulsion-based formulations of azole antifungal drugs have been developed for the treatment of skin infections caused by fungi.[80,81]

2. Transdermal delivery of larger molecules: Nanoparticles can also be used for the transdermal delivery of larger molecules, such as proteins and peptides. The use of nanoparticles can improve the permeation of these larger molecules across the skin barrier, resulting in enhanced efficacy and reduced side effects. For example, nanostructured lipid carriers have been used to deliver insulin through the skin for the treatment of diabetes.[82]
3. Combination therapy using nanoparticles for dermal drug delivery: Nanoparticles can be used for combination therapy, where two or more drugs are delivered simultaneously to the skin to treat a single condition. This approach can improve treatment outcomes and reduce the risk of drug resistance. For example, a combination of ciprofloxacin and terbinafine-loaded nanoparticles have been developed for the treatment of skin infections caused by bacteria and fungi.[83,84]

Current challenges and future prospects
Safety concerns of nanoparticle-based dermal drug delivery

Nanoparticle-based dermal drug delivery has shown promising results in preclinical studies and clinical trials, but safety concerns need to be addressed for their widespread use. The small size of nanoparticles allows them to penetrate the skin and enter the bloodstream, potentially causing toxicity. The toxicity of nanoparticles depends on their physicochemical properties, such as size, surface charge, and composition, as well as the route of administration and dose.[85]

Several studies have investigated the safety of nanoparticle-based dermal drug delivery, but the results are mixed. Some studies have reported no significant toxicity, while others have reported adverse effects such as skin irritation, inflammation, and tissue damage. Long-term studies are needed to determine the safety of nanoparticles in humans and to establish safe dose levels.[86]

Another concern is the potential environmental impact of nanoparticles, as they can accumulate in soil and water and affect ecosystems. Regulations for the use and disposal of nanoparticles need to be established to minimize their environmental impact.Despite these challenges, the future of nanoparticle-based dermal drug delivery looks promising. Advances in nanoparticle engineering and formulation can improve their safety and efficacy, and the development of new in vitro and in vivo models can better predict their behavior in humans. Nanoparticle-based dermal drug delivery has the potential to revolutionize the treatment of skin diseases and improve patient outcomes.[87]

Future directions and potential applications of nanoparticle technology for dermal drug delivery

Nanoparticle technology for dermal drug delivery is an evolving field with promising potential applications. Some future directions for research and development in this area include:

1. Developing new types of nanoparticles: While many types of nanoparticles have been explored for dermal drug delivery, there is still room for the development of new types of nanoparticles with unique characteristics that can enhance drug delivery and penetration.[88]
2. Targeted delivery: Developing targeted delivery systems that can deliver drugs specifically to certain skin layers or cell types can improve drug efficacy and reduce side effects.[89]
3. Combination therapies: Combining multiple drugs or therapeutic

agents in a single nanoparticle system can enable synergistic effects and improved therapeutic outcomes.[90]

4. Personalized medicine: Tailoring nanoparticle-based drug delivery to individual patients based on their specific skin type, age, and other factors can improve treatment efficacy and minimize side effects.[91]
5. Clinical translation: Moving nanoparticle-based dermal drug delivery from the laboratory to the clinic requires further research and development, as well as regulatory approval.[92]

3. Conclusion

In summary, nanoparticle-based dermal drug delivery has emerged as a promising strategy to overcome the limitations of conventional dermal drug delivery methods. Liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanostructured lipid carriers, and inorganic nanoparticles are the most commonly used types of nanoparticles for dermal drug delivery. The characteristics of nanoparticles, including size, surface charge, and surface chemistry, can significantly affect their dermal penetration and drug release. Formulation factors such as surfactants and stabilizers also play a crucial role in determining the efficacy of nanoparticle-based dermal drug delivery.

The application of nanoparticle-based dermal drug delivery has expanded to include topical delivery of small molecules, transdermal delivery of larger molecules, and combination therapy. However, there are still challenges that need to be addressed, including safety concerns, regulatory considerations, and the need for further research to optimize nanoparticle-based dermal drug delivery.

In the future, nanoparticle technology has the potential to revolutionize dermal drug delivery and lead to the development of more effective and safe therapies for a wide range of dermatological conditions. Further research is needed to fully understand the mechanisms of nanoparticle dermal penetration and to optimize the design and formulation of nanoparticles for specific drug delivery applications. Regulatory agencies need to establish guidelines for the evaluation and approval of nanoparticle-based dermal drug delivery systems, and clinicians need to be aware of the potential benefits and risks of using nanoparticle-based dermal drug delivery in clinical practice.

Acknowledgement

The conception and writing of this article were greatly assisted by all of the above authors.

Conflict of interest

The Authors declare no conflict of interest

4. References

1. Singh, M., & Singh, D. (2019). Transdermal drug delivery: Developmental issues and research initiatives. Journal of Drug Delivery Science and Technology, 51, 569-577.
2. Benson, H. A. (2012). Transdermal drug delivery: penetration enhancement techniques. Current drug delivery, 9(3), 245-252.
3. Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. Advanced drug delivery reviews, 56(5), 603-618.
4. Lademann, J., Otberg, N., Jacobi, U., Hoffman, R. M., Blume-Peytavi, U., & Sterry, W. (2009). Skin pharmacology and physiology. Boca Raton, FL: CRC Press.
5. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. European journal of pharmaceutical sciences, 14(2), 101-114.

6. Singh, B., & Beg, S. (2017). Nanoparticles: a new technology with wide applications. Research Journal of Pharmacy and Technology, 10(3), 819-828.
7. Chen, M., Xie, S., & Wei, X. (2019). Nanoparticle-based topical drug delivery systems for the treatment of dermatological diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 11(4), e1544.
8. Benson, H. A. (2005). Transdermal drug delivery: penetration enhancement techniques. Current drug delivery, 2(1), 23-33.
9. Fang, J. Y., Lee, W. R., & Shen, S. C. (2013). Transdermal delivery of macromolecules using skin electroporation: potential for antitumor vaccination. Journal of controlled release, 167(1), 40-47.
10. Singh, R., Lillard Jr, J. W., & Singh, S. (2009). Nanoformulations of drugs: Recent developments, impact and challenges. Biotechnology advances, 27(6), 715-733.
11. Gaspar, L. R., & Maia Campos, P. M. (2015). Application of nanotechnology in cosmetic and dermatological formulations: a review. International journal of cosmetic science, 37(6), 585-592.
12. Prow, T. W., Grice, J. E., & Roberts, M. S. (2011). Drug delivery options for the treatment of cutaneous infections. Current opinion in investigational drugs, 12(3), 265-278.
13. Kalaria, D. R., Sharma, G., Beniwal, V., & Ravi Kumar, M. N. V. (2016). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharmaceutical research, 33(10), 2494-2511.
14. Chen, L., Liu, Y., Wang, X., & Qiu, L. (2019). Nanoparticle-based drug delivery systems for application in dermatology. Asian journal of pharmaceutical sciences, 14(5), 480-489.
15. Parhi, R., & Suresh, P. (2012). Preparation and characterization of chitosan nanoparticles for improved dermal delivery of tretinoin. Journal of biomedical nanotechnology, 8(5), 795-802.
16. Singh, R., & Jain, A. (2019). Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. Journal of pharmacy & bioallied sciences, 11(4), 265-277.
17. Fonte, P., Araújo, F., Silva, C., Pereira, C., Reis, S., & Sarmento, B. (2013). Polymer-based nanoparticles for dermal drug delivery. Expert opinion on drug delivery, 10(4), 521-535.
18. Fang, J. Y., Hung, C. F., & Lin, Y. K. (2016). Liposomes as vehicles for enhancing dermal and transdermal delivery of therapeutic agents. International Journal of Nanomedicine, 11, 2703-2718. doi: 10.2147/IJN.S102956
19. Puglia, C., Sarpietro, M. G., Bonina, F., & Castelli, F. (2015). Lipid nanocarriers for dermal drug delivery. Expert Opinion on Drug Delivery, 12(8), 1419-1433. doi: 10.1517/17425247.2015.1023011
20. Lopes, L. B., & Scarpa, M. V. (2019). Dermal and transdermal drug delivery: challenges and innovations. Clinics in Dermatology, 37(5), 505-513. doi: 10.1016/j.clindermatol.2019.05.002
21. Barani, M., & Entezami, A. A. (2015). Preparation, characterization and optimization of liposomes containing clotrimazole for topical delivery. Advanced Pharmaceutical Bulletin, 5(1), 91-99. doi: 10.15171/apb.2015.015
22. Li, Y., He, X., Yin, L., & Tang, C. (2015). Effects of various formulation factors on the

characteristics of liposomes. International Journal of Pharmaceutics, 495(1), 407-419. doi: 10.1016/j.ijpharm.2015.08.015

23. Singh, R., Lillard Jr., J. W., & Singh, S. (2017). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 104(1), 44-55. doi: 10.1016/j.yexmp.2017.01.006
24. Jain, A. K., Thanki, K., Jain, S., & Agrawal, G. P. (2015). Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. Journal of Liposome Research, 25(3), 187-195. doi: 10.3109/08982104.2014.971204
25. Gupta, R., Rai, B., & Goyal, A. K. (2016). Polymeric nanoparticles for dermal and transdermal delivery of drugs and vaccines. Applied Microbiology and Biotechnology, 100(4), 1617-1626. doi: 10.1007/s00253-015-7173-3
26. Li, S. D., & Huang, L. (2010). Pharmacokinetics and biodistribution of nanoparticles. Molecular Pharmaceutics, 7(3), 311-323. doi: 10.1021
27. Jain, K., Kesharwani, P., Gupta, U., & Jain, N. K. (2013). Dendrimer toxicity: Let's meet the challenge. International Journal of Pharmaceutics, 456(1), 1-2. doi: 10.1016/j.ijpharm.2013.07.023
28. Roberts, M. S., Cross, S. E., & Pellett, M. A. (2012). Dendrimer-based topical delivery systems: Enhanced performance for the delivery of actives into the skin. European Journal of Pharmaceutics and Biopharmaceutics, 82(2), 229-238. doi: 10.1016/j.ejpb.2012.05.017
29. Garg, T., Rath, G., & Goyal, A. K. (2013). Dendrimers: Novel polymeric nanomaterials for drug delivery, skin care, and imaging. Journal of Applied Polymer Science, 130(6), 4019-4031. doi: 10.1002/app.39689
30. Menjoge, A. R., Kannan, R. M., & Tomalia, D. A. (2010). Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discovery Today, 15(5-6),
31. Müller, R. H., & Mäder, K. (2000). Glycerol monooleate nanosuspensions as vehicles for topical delivery: stability, rheology and visual appearance. International Journal of Pharmaceutics, 196(2), 137-148. doi: 10.1016/S0378-5173(99)00435-6
32. Jenning, V., Gohla, S. H., & Schäfer-Korting, M. (2000). Dermal drug delivery by nanoparticle-loaded microspheres. Advanced Drug Delivery Reviews, 45(1), 89-121. doi: 10.1016/S0169-409X(00)00117-0
33. Souto, E. B., Müller, R. H., & Cunha-Filho, M. (2004). Physicochemical characterization of ascorbyl palmitate nanoparticles and their behavior during in vitro release studies. Journal of Nanoscience and Nanotechnology, 4(1-2), 1-7. doi: 10.1166/jnn.2004.041
34. Liu, Y., Zhang, J., Wang, Y., & Luo, Y. (2018). Solid lipid nanoparticles for transdermal drug delivery. Journal of Nanomaterials, 2018, 1-13. doi: 10.1155/2018/7696272
35. Chen, Y., Wu, Q., Zhang, L., & Zhang, X. (2017). Nanostructured lipid carriers for topical delivery of hydrocortisone acetate. Journal of Drug Delivery Science and Technology, 39, 170-176. doi: 10.1016/j.jddst.2017.03.004
36. Wissing, S. A., & Müller, R. H. (2002). The influence of emulsifiers on the crystallization of solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 54(2), 165-170. doi: 10.1016/S0939-6411(02)00018-2

37. Singh, G., Dwivedi, H., Saraf, S., Saraf, S., & Asati, S. (2016). Nanostructured lipid carriers: an innovative platform for optimizing topical delivery of antifungal agents. Critical Reviews in Therapeutic Drug Carrier Systems, 33(5), 555-581. doi: 10.1615/CritRevTherDrugCarrierSyst.2016016125
38. Rao, Y. M., & Ramya, D. (2018). A review on nanotechnology-based approaches for the treatment of dermatophytosis. Journal of Microencapsulation, 35(2), 121-131. doi: 10.1080/02652048.2018.1437512
39. Pardeike, J., Hommoss, A., Müller, R. H. (2009). Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. International Journal of Pharmaceutics, 366(1-2), 170-184. doi: 10.1016/j.ijpharm.2008.10.003
40. Alkilani, A. Z., McCrudden, M. T., Donnelly, R. F. (2015). Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics, 7(4), 438-470. doi: 10.3390/pharmaceutics7040438
41. Barani, M., Honary, S., Ebrahimi, P., Jafari, H. (2016). A review of nanocarriers for dermal drug delivery. Journal of Nanomaterials, 2016, 1987636. doi: 10.1155/2016/1987636
42. Garg, T., Singh, O., Arora, S., Murthy, R. S. (2012). Solid lipid nanoparticles as carrier for topical delivery of aceclofenac. AAPS PharmSciTech, 13(3), 1247-1254. doi: 10.1208/s12249-012-9865-7
43. Gomaa, Y. A., Garland, M. J., McInnes, F., Donnelly, R. F., El-Khordagui, L. K. (2013). Dendrimers for enhanced topical drug delivery. Therapeutic Delivery, 4(6), 657-675. doi: 10.4155/tde.13.32
44. Hu, L., Zhang, Y., Gao, W., Feng, S. S. (2016). Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Journal of Controlled Release, 233, 64-72. doi: 10.1016/j.jconrel.2016.05.023
45. Sinico, C., Fadda, A. M., & Sanna, V. (2012). Recent advances in nanoparticle-based delivery systems for anti-inflammatory drugs. Pharmaceutics, 4(4), 608-627.
46. Patzelt, A., Lademann, J., Richter, H., Darvin, M. E., Schanzer, S., Thiede, G., ... & Sterry, W. (2011). Cutaneous penetration of lipophilic drugs: comparison of two different in vitro test systems with in vivo human data. Skin pharmacology and physiology, 24(5), 199-206.
47. Gomaa, Y. A., Garland, M. J., & McInnes, F. J. (2011). Donnan potential and zeta potential of lipid nanoparticle formulations containing ionizable lipids: studies using fluorescence probe. International journal of pharmaceutics, 415(1-2), 329-334.
48. Müller, R. H., & Mäder, K. (2012). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced drug delivery reviews, 64, 170-181.
49. Wang, Y., Yuan, Y., Du, L., Liu, X., & Ding, J. (2016). Characterization and in vitro penetration of different types of nanoparticles in porcine skin. Colloids and Surfaces B: Biointerfaces, 147, 283-291.
50. Karande, P., Mitragotri, S., & Lahann, J. (2009). Nanocarriers for transdermal drug delivery. Journal of drug targeting, 17(3), 167-174.
51. Chen, Y., Chen, H., Shi, J., Ino, Y., Nakamura, T., & Fukushima, S. (2017). Nanoparticles for improving skin penetration: a review of recent research and future perspectives.

Journal of drug targeting, 25(1), 17-24.
52. Lboutounne, H., Faivre, V., Falson, F., Pirot, F., & Falson, P. (2007). Skin penetration of a dipalmitoylphosphatidylcholine-based liposome containing the ion-pair complex glycyrrhetinic acid-potassium. European journal of pharmaceutics and biopharmaceutics, 67(3), 698-705.
53. Pople, P. V., Singh, K. K., & Mishra, V. (2010). Enhanced topical delivery of an anti-fungal agent using a nanostructured lipid carrier-based gel formulation. Chemical and Pharmaceutical Bulletin, 58(4), 544-550.
54. Song, C. K., Balakrishnan, P., & Shim, C. K. (2010). Enhanced skin permeation of finasteride using polymeric microneedles: in vitro characterization and in vivo evaluation. Pharmaceutical research, 27(10), 2217-2224.
55. Singh B, Garg T, Goyal AK, Rath G. Nanostructured lipid carriers: an emerging platform for improving topical delivery of anti-fungal agents. J Drug Deliv Sci Technol. 2019;51:328-339. doi: 10.1016/j.jddst.2018.12.023
56. Kaur IP, Kakkar V, Deol PK, Yadav M, Singh R. Dermal drug delivery: a focus on nanoparticles. Pharmaceutics. 2020;12(4):305. doi: 10.3390/pharmaceutics12040305
57. Pople PV, Singh KK. Targeted delivery of antifungal agents using nanotechnology. In: Rai M, Ribeiro C, Mattoso L, Durán N, editors. Nanotechnologies in Food and Agriculture. Springer; 2019. p. 135-153. doi: 10.1007/978-3-030-34022-6_7
58. Song CK, Balakrishnan P, Shim WS. Enhanced drug delivery efficiency of polymeric nanoparticles by electrospraying technique for topical treatment of psoriasis. Colloids Surf B Biointerfaces. 2017;150:475-483. doi: 10.1016/j.colsurfb.2016.11.054
59. Gupta V, Jain S, Chandra A, et al. Novel drug delivery systems for sustained anti-fungal activity. J Control Release. 2018;287:49-65. doi: 10.1016/j.jconrel.2018.08.037
60. Gupta, A., & Prausnitz, M. R. (2013). Intermittent nanoparticle delivery enhances skin permeability and transdermal penetration. Journal of Controlled Release, 170(2), 200-205.
61. Lademann, J., Otberg, N., Jacobi, U., & Sterry, W. (2009). Penetration and storage of particles in human skin: perspectives and safety aspects. Advances in Experimental Medicine and Biology, 655, 124-135.
62. Prow, T. W., Grice, J. E., Lin, L. L., Faye, R., Butler, M., Becker, W., ... & Roberts, M. S. (2011). Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery Reviews, 63(6), 470-491.
63. Tinkle, S. S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. C., ... & Brinke, A. (2014). Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 1313(1), 35-56.
64. Zhang, L. W., Monteiro-Riviere, N. A., & Mechanisms of Quantum Dot Nanoparticle Penetration into Skin Cells. (2009). Toxicological Sciences, 110(1), 138-155.
65. Baroli, B. (2010). Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? Journal of pharmaceutical sciences, 99(1), 21-50.
66. Chaudhari, S. P., Chaudhari, Y. S., & Patel, V. A. (2018). Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 14(8), 2361-2382.
67. de Oliveira, C. C., Seabra, A. B., Durán, N., & Pelegrino, M. T. (2019). Physicochemical properties

of nanoparticles regulating their skin penetration. In Nanoparticles for skin delivery (pp. 1-26). Elsevier.
68. Labouta, H. I., & El-Khordagui, L. K. (2018). Nanoparticles for skin penetration enhancement—A review of recent advancements. Current Pharmaceutical Design, 24(25), 2989-3006.
69. Patzelt, A., Lademann, J., Richter, H., Darvin, M. E., & Schanzer, S. (2019). Nanoparticles in dermatology. Archives of dermatological research, 311(2), 83-91.
70. Alkilani, A. Z., & McCrudden, M. T. (2015). Donnan potential and polyelectrolyte properties of hyaluronic acid: implications for dermal delivery. Journal of pharmaceutical sciences, 104(6), 1826-1834.
71. Carbone, C., & Campisi, A. (2018). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nanomaterials, 8(8), 557.
72. Liu, Q., Li, R., & Li, Y. (2020). Skin-targeted delivery of therapeutics: a review of recent advances and challenges. Journal of controlled release, 327, 682-705.
73. Singh, R., Lillard Jr, J. W., & Singh, S. (2009). Nanoparticle-based targeted drug delivery. Experimental and molecular pathology, 86(3), 215-223.
74. Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Singh, S. R. (2019). Application of nanotechnology in drug delivery. In Nanotechnology in modern medicine (pp. 31-68). Academic Press.
75. Abdulbaqi, I. M., Darwis, Y., & Khan, N. A. (2016). Nanoparticles in dermatology: current perspectives. International journal of nanomedicine, 11, 3537–3561. https://doi.org/10.2147/IJN.S108308
76. Firoz, A., Nair, R., & Rajan, M. (2019). Dermal drug delivery using nanoparticles: A review. International journal of pharmaceutics, 558, 248–264. https://doi.org/10.1016/j.ijpharm.2018.11.035
77. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature biotechnology, 26(11), 1261–1268. https://doi.org/10.1038/nbt.1504
78. Singh, M., Singh, D., & Manchanda, G. (2019). Recent Advances in Nanoparticles-Based Topical Drug Delivery Systems for the Treatment of Skin Diseases. Current drug metabolism, 20(7), 547–560. https://doi.org/10.2174/1389200219666180903110107
79. Wissing, S. A., & Müller, R. H. (2003). Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. Journal of controlled release, 89(2), 145–156. https://doi.org/10.1016/S0168-3659(03)00092-6
80. Jain, A. K., Garg, N. K., & Jain, A. (2016). Nanoparticles for transdermal drug delivery. Current drug delivery, 13(5), 662-671.
81. Goyal, R., & Macri, L. K. (2019). Nanoparticles as drug delivery systems for skin delivery of drugs. In Dermatologic drug delivery (pp. 95-120). CRC Press.
82. Manconi, M., Caddeo, C., Sinico, C., Valenti, D., & Fadda, A. M. (2016). Nanoparticulate carriers for dermal delivery of cosmetic active ingredients. International journal of pharmaceutics, 506(1-2), 130-137.
83. Puri, A., Loomis, K., Smith, B., Lee, J. H., & Yavlovich, A. (2009). Factors affecting the dermal absorption of nanoparticles. In Nanoparticles in biology and medicine (pp. 121-138). Springer, Boston, MA.

84. Narang, A. S., Desai, D. S., & McCoy, C. P. (2009). Development of in vitro-in vivo correlation for nanoparticle drug delivery systems: a case study. Journal of pharmaceutical sciences, 98(12), 4654-4669.
85. Niska K, Zielinska A, Puszko A, et al. Nanoparticles as a Potential Tool for Skin Cancer Diagnosis and Treatment. Nanomaterials (Basel). 2020;10(2):345. doi:10.3390/nano10020345
86. Larese Filon F, Crosera M, Adami G, et al. Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology. 2009;255(1-2):33-37. doi:10.1016/j.tox.2008.09.025
87. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-491. doi:10.1016/j.addr.2011.01.006
88. Chen, Y., Liang, L., Li, C., Li, B., & Li, Y. (2020). Recent advances in nanotechnology-based drug delivery systems for the topical treatment of skin diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 12(3), e1615.
89. Gupta, P. N., & Mishra, V. (2020). Therapeutic potential of nanotechnology in dermatology. Nanomedicine: Nanotechnology, Biology and Medicine, 28, 102222.
90. Jiang, L., Wang, X., Lin, Z., & Xiang, B. (2020). Nanostructured lipid carriers and their application in topical drug delivery. Journal of Controlled Release, 327, 607-623.
91. Joshi, S., & Kumar, P. (2019). Nanoparticle-based topical drug delivery systems for the treatment of dermatological diseases: A review. Pharmaceutical Nanotechnology, 7(1), 12-27.
92. Singh, A., Nanda, S., Kotla, N. G., El-Hage, N., Kaur, I. P., & Mishra, Y. K. (2019). Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release: A potential approach for the treatment of ocular inflammation. Pharmaceutical Nanotechnology, 7(3), 228-244.